Galecto, Inc.
Clinical-stage biotech developing small molecule therapeutics for cancer and liver disease.
GLTO | US
Overview
Corporate Details
- ISIN(s):
- US36322Q1076
- LEI:
- Country:
- United States of America
- Address:
- 75 STATE STREET, 2109 BOSTON
- Website:
- https://galecto.com/
- Sector:
- Manufacturing
Description
Galecto, Inc. is a clinical-stage biotechnology company that develops novel small molecule therapeutics for cancer and severe liver diseases. The company leverages its expertise in galectin biology to create product candidates that modulate central disease pathways. Its pipeline focuses on inhibitors of key proteins such as galectin-3 and LOXL2, which are implicated in fibrosis and cancer progression. In October 2024, Galecto expanded its oncology portfolio by acquiring GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of multiple genetic subsets of acute myeloid leukemia (AML). The company's research also targets other cancers, including melanoma, head and neck squamous cell carcinoma (HNSCC), and hepatocellular carcinoma (HCC). Galecto's mission is to develop safe and effective treatments that significantly improve patient quality of life.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Galecto, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Galecto, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Galecto, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
